Enanta Pharmaceuticals Inc (ENTA) Files 10-K for the Fiscal Year Ended on September 30, 2018

Enanta Pharmaceuticals Inc (ENTA, Financial) files its latest 10-K with SEC for the fiscal year ended on September 30, 2018. Enanta Pharmaceuticals Inc is a biotechnology company. It is engaged in the research and development of small molecule drugs for infectious diseases. The Group uses its chemistry-driven approach & drug discovery capabilities to develop its products. Enanta Pharmaceuticals Inc has a market cap of $1.6 billion; its shares were traded at around $82.62 with a P/E ratio of 23.80 and P/S ratio of 7.87.

For the last quarter Enanta Pharmaceuticals Inc reported a revenue of $67.2 million, compared with the revenue of $75.93 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $206.6 million, an increase of 101% from last year. For the last five years Enanta Pharmaceuticals Inc had an average revenue growth rate of 37% a year.

The reported diluted earnings per share was $3.48 for the year, an increase of 282.4% from previous year. The Enanta Pharmaceuticals Inc enjoyed an operating margin of 42.75%, compared with the operating margin of 23.94% a year before. The 10-year historical median operating margin of Enanta Pharmaceuticals Inc is 37.36%. The profitability rank of the company is 5 (out of 10).

At the end of the fiscal year, Enanta Pharmaceuticals Inc has the cash and cash equivalents of $63.9 million, compared with $65.7 million in the previous year. The company had no long term debt, compared with $0.38 million in the previous year. Enanta Pharmaceuticals Inc has a financial strength rank of 10 (out of 10).

At the current stock price of $82.62, Enanta Pharmaceuticals Inc is traded at close to its historical median P/S valuation band of $81.63. The P/S ratio of the stock is 7.87, while the historical median P/S ratio is 7.79. The stock gained 73.98% during the past 12 months.

For the complete 20-year historical financial data of ENTA, click here.